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Abstract
Fifteen different taxoid conjugates were prepared by linking various anticancer compounds,
including camptothecin (CPT), epipodophyllotoxin (EP), colchicine (COL), and glycyrrhetinic acid
(GA), at the 2’- or 7-position on paclitaxel (TXL, 1) through an ester, imine, amine, or amide bond.
Newly synthesized conjugates were evaluated for cytotoxic activity against replication of several
human tumor cell lines. Among them, TXL-CPT conjugates, 8–10, were more potent than TXL itself
against the human prostate carcinoma cell line PC-3 (ED50 = 14.8, 3.1, 19.4 nM compared with 55.5
nM), and conjugate 10 was also eightfold more active than TXL against the LN-CAP prostate cancer
cell line. These compounds also possessed anti-angiogenesis ability as well as lower inhibitory effects
against a normal cell line (MRC-5). Thus, conjugates 8–10 are possible antitumor drug candidates,
particularly for prostate cancer.
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Paclitaxel (TXL, 1, Figure 1), a plant derived antimitotic agent,1–2 is currently in clinical use
against ovarian and breast cancer. It promotes the irreversible assembly of tubulin into
microtubules by binding to and stabilizing microtubules. This mechanism of action is unique
among the established antitumor drugs, including the vinca alkaloids, vincristine and
vinblastine, which prevent microtubule assembly by microtubule binding.3 Other natural
products, including camptothecin (CPT),4 which is approved for clinical use in the United
State, epipodophyllotoxin (EP),5 and colchicine (COL),6 also possess potent antitumor
activities with different mechanisms of action3 from TXL. Some EP derivatives, such as
etoposide (2d), topotecan, and irinotecan, are approved by the FDA for cancer treatment,
although their therapeutic use is often limited by undesired side effects, such as
myelosuppression, multidrug resistance and poor water solubility. In addition, glycyrrhetinic
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acid (GA),7 which is a well-known natural compound isolated from plants, shows antitumor-
promoter activity, as well as anti-allergic, anti inflammatory, and anti-ulcer effects.
Conjugation of two antitumor agents with different mechanisms of action can possibly augment
the potency of both compounds or reduce the side effects and drug-resistance development.
We have already reported the unique antitumor activities of such conjugates, including TXL-
CPT,8 TXL-EP,9 and CPT-EP.10 In our continuous effort to develop new classes of antitumor
agents based on TXL, we investigated the syntheses and evaluation of TXL conjugates with
the above mentioned antitumor or antitumor-promoter compounds through various linkages at
the TXL C-2’ and C-7 positions as reported herein.
Newly synthesized conjugates are shown in Figure 2. In conjugates 6–15, EP, CPT, COL, and
GA are connected to the TXL C-2’ position through various linkages, while conjugates 16–
21 contain EP, COL, and GA connected to the C-7 position of TXL. As shown in Scheme 1,
a linking group was introduced directly at the TXL C-2’ position using the appropriate
anhydride or carboxylic acid to provide 22–25.11 For the C-7 linked conjugates, the TXL C-2’
hydroxyl group was first protected with a Cbz or TBS group, the linking carboxylic acid was
added at C-7, and the protecting group was then removed to afford 26–28. Compounds 22–
24, 26, and 27 were conjugated with EP derivative 2c,12 COL derivatives 4b–d,13 and GA
(5), respectively, by using EDCI in the presence of DMAP to provide 6, 7, 11–13, 15–17, and
21. Heating intermediates 22 and 23 with 7-formyl-CPT (3b)14 in benzene produced the
corresponding imines 8 and 10, respectively. In the same way, imines 14, 18, and 20 were
prepared from 25 with 4d and 28 with 2b or 4d, respectively. Hydrogenation of 8 and 18
produced the corresponding amines 9 and 19.
All synthesized compounds were evaluated for cytotoxic activity against replication of several
human tumor cell lines, human ovarian carcinoma (1A9), human lung carcinoma (A549),
breast cancer (MCF-7), human prostate carcinoma (LN-CAP, PC-3, DU-145), human
epidermoid of the nasopharynx (KB), and multi-drug resistant expressing P-glycoprotein (KB-
VIN) and against the normal cell line, human embryonic fibroblast (MRC-5). The results are
shown in Table 1 with the values for TXL (1), EP derivatives 2b–c, etoposide (2d), CPT
(3a), 7-formyl-CPT (3b), 2-demethyl-COL (4b), 2-demthylthio-COL (4c), and GA (5) for
comparison. All conjugated compounds showed better activity than the partner compounds,
although most of them were less potent than TXL itself. However, TXL-CPT conjugates 8–
10 displayed different patterns of inhibition against the LN-CAP and PC-3 prostate cancer cell
lines, with less effect on the normal cell line, MRC-5. Imine 10 had an ED50 value of 0.34 nM
and was 7.7-fold more potent than TXL against LN-CAP cells, while compound 9 had an
ED50 value of 3.1 nM and was 18-fold more potent than TXL against PC-3 cells.
Cytotoxic activity was somewhat dependant on the conjugated position on TXL as well as the
type of linkage. From comparison of the TXL-EP conjugates 6, 7, 16, and 17, the conjugates
linked at the C-2’ position (6, 7) showed better activity than conjugates linked at the C-7
position (16, 17) against all cell lines. Moreover, the linkage with two methylenes (6, 16) gave
better results than the one with three methylenes (7, 17). However, TXL-COL conjugates 14
(2’-linkage) and 20 (7-linkage) showed similar potency against most cell lines. A phenyl imino
linkage was better than the linear amido linkage, as TXL-COL conjugate 14 was four- to nine-
fold more potent than 13 against 1A9, A549, and KB cells.
The results of selected compounds in an anti-angiogenesis assay are shown in Table 2.
Compared with the other conjugates, imines 8 and 10 possessed significant activity with
ED50 values of 0.73 and 0.98 μg/mL, respectively.
In conclusion, we have synthesized fifteen different conjugates between paclitaxel (TXL) and
other antitumor agents, including camptothecin (CPT), epipodophyllotoxin (EP), colchicine
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(COL), and glycyrrhetinic acid (GA). The two components were joined by an ester, imine,
amine or amide linkage at the 2’- or 7-position of TXL. Among them, TXL-CPT conjugates,
8–10, showed different in vitro cytotoxic activity profiles against human prostate carcinoma,
LN-CAP and PC-3, with less effect against normal cells. These compounds also possessed
anti-angiogenesis ability; therefore, conjugates 8–10 are possible antitumor drug candidates,
particularly for prostate cancer.
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Structures of paclitaxel (1) and other antitumor agents used for conjugation.
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Table 2
Anti-angiogenesis assay data of selected compounds in HUVEC cells
Compound ED50 (nM) Compound ED50 (nM)
6 4.93 13 15.8
8 0.73 14 43.0
9 2.09 18 230
10 0.98 20 293
11 13.84 21 150
12 9.33
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